Bio-Rad buys Ciphergen proteomics instrument unit
This article was originally published in The Gray Sheet
Executive Summary
Bio-Rad Laboratories' $20 mil. cash purchase of Ciphergen Biosystems' proteomics instrument business, announced Aug. 14, includes surface enhanced laser desorption/ionization (SELDI) technology for life sciences applications and ProteinChip arrays and related software. Under the terms of the transaction, which includes a $3 mil. Bio-Rad equity investment in Ciphergen, the latter firm will retain SELDI rights for diagnostic applications. The deal furthers Ciphergen's strategy to focus on cancer diagnostics and other tests...